Edgewise Therapeutics (EWTX) Depreciation and Depletion (2024 - 2026)

Edgewise Therapeutics has reported Depreciation and Depletion for 7 years, with the latest figure at $537000.0 in Q1 2026.

• Quarterly Depreciation and Depletion rose 4.68% year-over-year to $537000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (down 2.93% YoY) and the FY2025 annual result came in at $2.1 million, up 0.72% from the prior year.
• Depreciation and Depletion grew to $537000.0 in Q1 2026 per EWTX's latest filing, from $484000.0 in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $569000.0 in Q4 2024 and troughed at $100000.0 in Q1 2022.
• A 5-year average of $380647.1 and a median of $484000.0 in 2025 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2023 and 2025: Depreciation and Depletion surged 400.0% in 2023, then declined 14.94% in 2025.
• Over 5 years, Depreciation and Depletion stood at $100000.0 in 2022, then soared by 400.0% to $500000.0 in 2023, then climbed by 13.8% to $569000.0 in 2024, then slipped by 14.94% to $484000.0 in 2025, then gained by 10.95% to $537000.0 in 2026.
• According to Business Quant data, Depreciation and Depletion over the past three periods registered $537000.0, $484000.0, and $500000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.